Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents-Reference-Cited by-同舟云学术

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

Published:2011-12-23 Issue:5 Volume:156 Page:619-625
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Sibon David,Cannas Giovanna,Baracco Fiorenza,Prebet Thomas,Vey Norbert,Banos Anne,Besson Caroline,Corm Selim,Blanc Michel,Slama Bohrane,Perrier Hervé,Fenaux Pierre,Wattel Eric,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08979.x/fullpdf

Reference27 articles.

1. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study;Ades;Blood,2009

2. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study;Balleari;Annals of Hematology,2006

3. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications;Chang;Blood,2006

4. Report of an international working group to standardize response criteria for myelodysplastic syndromes;Cheson;Blood,2000

5. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia;Cheson;Blood,2006

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes, Survival, and Predictors in Lower-Risk Myelodysplastic Syndrome Patients Treated with Cyclosporine A;Acta Haematologica;2024-02-17

2. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years;Expert Review of Anticancer Therapy;2020-06-01

3. Evolving therapies for lower-risk myelodysplastic syndromes;Annals of Hematology;2020-02-20

4. Myelodysplastic Syndromes: An Update on Pathophysiology and Management;Recent Developments in Myelodysplastic Syndromes;2019-02-20

5. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28